AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
May 09 2024 - 8:50AM
UK Regulatory
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on
May 16, 2024, and Host Conference Call and Webcast
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) --
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”) announced today that
management will host a conference call and webcast to discuss the
Company’s Q1 2024 operational and financial results on Thursday,
May 16, 2024, at 8:30 AM ET.
The call will be hosted by members of AIM’s
leadership team, Thomas K. Equels, Chief Executive Officer and
Christopher McAleer, PhD, Scientific Officer. Interested
participants and investors may access the conference call by
dialing (877) 407-9219 (domestic) or (201) 689-8852 (international)
and referencing the AIM ImmunoTech Conference Call. The webcast
will be accessible on the Events page of the Investors section of
the Company’s website, aimimmuno.com, and will be archived for 90
days following the live event.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a
dsRNA and highly selective TLR3 agonist immuno-modulator with broad
spectrum activity in clinical trials for globally important
cancers, viral diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on X, LinkedIn, and Facebook.
Aim Immunotech (LSE:0A4Y)
Historical Stock Chart
From Nov 2024 to Dec 2024
Aim Immunotech (LSE:0A4Y)
Historical Stock Chart
From Dec 2023 to Dec 2024
